JP2007530498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530498A5 JP2007530498A5 JP2007504378A JP2007504378A JP2007530498A5 JP 2007530498 A5 JP2007530498 A5 JP 2007530498A5 JP 2007504378 A JP2007504378 A JP 2007504378A JP 2007504378 A JP2007504378 A JP 2007504378A JP 2007530498 A5 JP2007530498 A5 JP 2007530498A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- pharmaceutical composition
- hydroxy tamoxifen
- composition according
- isomer form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (12)
- 約45%〜55%、約46%〜54%、約47%〜53%、約48%〜52%、約49%〜51%または約50%の4−ヒドロキシタモキシフェンがZ異性体の形態で存在し、残りの4−ヒドロキシタモキシフェンがE異性体の形態で存在する、4−ヒドロキシタモキシフェンを含む、平衡状態の医薬組成物。
- 経皮投与用に製剤されている請求項1に記載の医薬組成物。
- アルコールおよび/または浸透促進剤をさらに含む請求項2に記載の医薬組成物。
- 前記4−ヒドロキシタモキシフェンが、水性アルコールゲル、水性アルコール溶液、貼付剤、軟膏、クリーム、乳濁液(ローション)、散剤またはオイルに製剤されている請求項2に記載の医薬組成物。
- 前記4−ヒドロキシタモキシフェンが、水性アルコールゲルに製剤されている請求項4に記載の医薬組成物。
- 前記水性アルコールゲルが、エタノール、ミリスチン酸イソプロピル、およびヒドロキシプロピルセルロースを含む請求項5に記載の医薬組成物。
- この医薬組成物が、
a)約0.01重量%〜0.2重量%の4−ヒドロキシタモキシフェン、
b)約0.5重量%〜2重量%のミリスチン酸イソプロピル、
c)約60重量%〜75重量%の無水アルコール、
d)約25重量%〜40重量%の水系媒体、
e)約0.5重量%〜5重量%のゲル化剤
を含み;
成分の前記パーセントが、前記組成物の重量に対する重量である請求項2に記載の医薬組成物。 - 単位用量小袋内または計量ポンプ付きの複数用量容器内に入れられている請求項7に記載の医薬組成物。
- (i)所定量の4−ヒドロキシタモキシフェンを準備する工程と、
(ii)少なくとも1種の賦形剤を準備する工程と、
(iii)前記4−ヒドロキシタモキシフェンと前記少なくとも1種の賦形剤とを組み合わせることにより、医薬組成物を形成する工程と、
(iv)前記医薬組成物を、約45%〜55%、約46%〜54%、約47%〜53%、約48%〜52%、約49%〜51%または約50%の4−ヒドロキシタモキシフェンがZ異性体の形態で存在し、残りの4−ヒドロキシタモキシフェンがE異性体の形態で存在する平衡状態にする工程と
を有する医薬組成物を製造する方法。 - 前記医薬組成物が経皮投与用のものである請求項9に記載の方法。
- 前記医薬組成物が、
a)約0.01重量%〜0.2重量%の4−ヒドロキシタモキシフェン、
b)約0.5重量%〜2重量%のミリスチン酸イソプロピル、
c)約60重量%〜75重量%の無水アルコール、
d)約25重量%〜40重量%の水系媒体、
e)約0.5重量%〜5重量%のゲル化剤
を含み;
成分の前記パーセントが、前記組成物の重量に対する重量である請求項9に記載の方法。 - 請求項9〜11のいずれかに記載の方法で得られる医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/805,530 US20050208139A1 (en) | 2004-03-22 | 2004-03-22 | Chemically stable compositions of 4-hydroxy tamoxifen |
US10/805,530 | 2004-03-22 | ||
EP04290762.6 | 2004-03-22 | ||
EP04290762A EP1579857A1 (en) | 2004-03-22 | 2004-03-22 | Chemically stable compositions of 4-hydroxy tamoxifen |
PCT/EP2005/003455 WO2005092310A2 (en) | 2004-03-22 | 2005-03-18 | Chemically stable compositions of 4-hydroxy tamoxifen |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2007530498A JP2007530498A (ja) | 2007-11-01 |
JP2007530498A5 true JP2007530498A5 (ja) | 2008-05-08 |
JP5489407B2 JP5489407B2 (ja) | 2014-05-14 |
Family
ID=34854723
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007504378A Active JP5489407B2 (ja) | 2004-03-22 | 2005-03-18 | 4−ヒドロキシタモキシフェンの化学的に安定な組成物 |
Country Status (22)
Country | Link |
---|---|
US (1) | US20050208139A1 (ja) |
EP (4) | EP1579857A1 (ja) |
JP (1) | JP5489407B2 (ja) |
CN (1) | CN101080222B (ja) |
AR (1) | AR048587A1 (ja) |
AT (1) | ATE453387T1 (ja) |
AU (1) | AU2005227073B2 (ja) |
CA (1) | CA2557806C (ja) |
DE (1) | DE602005018613D1 (ja) |
DK (1) | DK1727532T3 (ja) |
ES (3) | ES2517894T3 (ja) |
HK (2) | HK1098674A1 (ja) |
IL (2) | IL177778A (ja) |
MX (1) | MXPA06010928A (ja) |
NO (1) | NO337298B1 (ja) |
NZ (1) | NZ549664A (ja) |
PL (1) | PL1727532T3 (ja) |
PT (1) | PT1727532E (ja) |
RU (1) | RU2389483C2 (ja) |
TW (1) | TWI401078B (ja) |
WO (1) | WO2005092310A2 (ja) |
ZA (1) | ZA200607291B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60305068T2 (de) | 2002-12-18 | 2007-01-11 | Laboratoires Besins International | Behandlung von mastalgie mit 4-hydroxy-tamoxifen |
EP2050443B1 (en) * | 2002-12-18 | 2017-05-24 | Besins Healthcare Luxembourg SARL | Reduction of breast density with 4-hydroxy tamoxifen |
EP1941871B1 (en) | 2003-04-01 | 2014-01-08 | Besins Healthcare Luxembourg SARL | Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
US7767717B2 (en) | 2003-06-09 | 2010-08-03 | Ascend Therapeutics, Inc. | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
EP1799201B1 (en) * | 2004-10-14 | 2008-11-26 | Laboratoires Besins International | 4-hydroxy tamoxifen gel formulations |
CA2775266C (en) * | 2009-10-13 | 2013-12-31 | Duquesne University Of The Holy Spirit, A Nonprofit Corporation Organized Under The Laws Of The Commonwealth Of Pennsylvania | Anti-cancer tamoxifen-melatonin hybrid ligand |
US10016370B2 (en) * | 2011-07-14 | 2018-07-10 | Able Cerebral, Llc | Composition, device and method for delayed and sustained release of brain energy molecules |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
US5475851A (en) * | 1986-04-14 | 1995-12-12 | National Instruments Corporation | Method and apparatus for improved local and global variable capabilities in a graphical data flow program |
US5002938A (en) * | 1988-03-21 | 1991-03-26 | Bristol-Myers Squibb Company | Antifungal gel formulations |
CA2032695A1 (en) | 1989-12-20 | 1991-06-21 | Hiroshi Akimoto | Condensed heterocyclic compounds, their production and use |
DE4407742C1 (de) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat |
US5809266A (en) * | 1994-07-29 | 1998-09-15 | Oracle Corporation | Method and apparatus for generating reports using declarative tools |
DE4435784C2 (de) * | 1994-10-06 | 1998-10-29 | Heraeus Electro Nite Int | Elektrisch beheizbarer Starterkat |
US5777621A (en) * | 1994-12-22 | 1998-07-07 | Apple Computer, Inc. | Quality control mechanism for three-dimensional graphics rendering |
CA2243330A1 (en) * | 1996-01-20 | 1997-07-24 | Ioana Popa | Tamoxifen and analogues thereof |
DE59703511D1 (de) * | 1996-03-29 | 2001-06-13 | S W Patentverwaltungs Ges M B | Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite" |
US6083996A (en) * | 1997-11-05 | 2000-07-04 | Nexmed Holdings, Inc. | Topical compositions for NSAI drug delivery |
AU2513899A (en) * | 1997-12-23 | 1999-07-19 | Hexal Ag | Mixture and pharmaceutical composition comprising z-4-hydroxytamoxifen and cyclodextrin |
JP2000038335A (ja) * | 1998-07-22 | 2000-02-08 | Kanebo Ltd | 皮膚化粧料 |
EP1212325A2 (en) | 1999-08-23 | 2002-06-12 | Eli Lilly And Company | A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
AU2002340120A1 (en) * | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
PT1317921E (pt) * | 2001-12-07 | 2009-11-06 | Besins Mfg Belgium | Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações |
US6695171B2 (en) * | 2002-02-12 | 2004-02-24 | Seaquistperfect Dispensing Foreign, Inc. | Pump dispenser |
EP2050443B1 (en) * | 2002-12-18 | 2017-05-24 | Besins Healthcare Luxembourg SARL | Reduction of breast density with 4-hydroxy tamoxifen |
DE60305068T2 (de) * | 2002-12-18 | 2007-01-11 | Laboratoires Besins International | Behandlung von mastalgie mit 4-hydroxy-tamoxifen |
EP1941871B1 (en) * | 2003-04-01 | 2014-01-08 | Besins Healthcare Luxembourg SARL | Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
US7767717B2 (en) * | 2003-06-09 | 2010-08-03 | Ascend Therapeutics, Inc. | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
WO2005058297A1 (en) * | 2003-12-15 | 2005-06-30 | Laboratoires Besins International | Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia |
US7507769B2 (en) * | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
-
2004
- 2004-03-22 EP EP04290762A patent/EP1579857A1/en not_active Withdrawn
- 2004-03-22 US US10/805,530 patent/US20050208139A1/en not_active Abandoned
-
2005
- 2005-03-18 DK DK05735277.5T patent/DK1727532T3/da active
- 2005-03-18 MX MXPA06010928A patent/MXPA06010928A/es active IP Right Grant
- 2005-03-18 CA CA2557806A patent/CA2557806C/en active Active
- 2005-03-18 EP EP09175781.5A patent/EP2147670B1/en active Active
- 2005-03-18 PL PL05735277T patent/PL1727532T3/pl unknown
- 2005-03-18 EP EP05735277A patent/EP1727532B1/en active Active
- 2005-03-18 AT AT05735277T patent/ATE453387T1/de active
- 2005-03-18 EP EP10180921A patent/EP2269599B1/en active Active
- 2005-03-18 CN CN200580009171XA patent/CN101080222B/zh active Active
- 2005-03-18 PT PT05735277T patent/PT1727532E/pt unknown
- 2005-03-18 JP JP2007504378A patent/JP5489407B2/ja active Active
- 2005-03-18 ES ES09175781.5T patent/ES2517894T3/es active Active
- 2005-03-18 ES ES05735277T patent/ES2337069T3/es active Active
- 2005-03-18 WO PCT/EP2005/003455 patent/WO2005092310A2/en active Search and Examination
- 2005-03-18 ES ES10180921T patent/ES2402921T3/es active Active
- 2005-03-18 RU RU2006137282/15A patent/RU2389483C2/ru active
- 2005-03-18 DE DE602005018613T patent/DE602005018613D1/de active Active
- 2005-03-18 AU AU2005227073A patent/AU2005227073B2/en active Active
- 2005-03-18 NZ NZ549664A patent/NZ549664A/en unknown
- 2005-03-21 TW TW094108588A patent/TWI401078B/zh active
- 2005-03-22 AR ARP050101125A patent/AR048587A1/es unknown
-
2006
- 2006-08-30 IL IL177778A patent/IL177778A/en active IP Right Grant
- 2006-08-31 ZA ZA2006/07291A patent/ZA200607291B/en unknown
- 2006-10-20 NO NO20064765A patent/NO337298B1/no unknown
-
2007
- 2007-04-20 HK HK07104159.2A patent/HK1098674A1/xx unknown
-
2010
- 2010-06-23 HK HK10106178.9A patent/HK1139332A1/xx unknown
-
2011
- 2011-10-25 IL IL215897A patent/IL215897A/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007530498A5 (ja) | ||
JP7187522B2 (ja) | 勃起不全および他の適応症の処置 | |
Barkin | Topical nonsteroidal anti-inflammatory drugs: the importance of drug, delivery, and therapeutic outcome | |
Egorova et al. | Cytotoxic activity of salicylic acid-containing drug models with ionic and covalent binding | |
Liu et al. | Protective effects of quercetin against pyrazinamide induced hepatotoxicity via a cocrystallization strategy of complementary advantages | |
BRPI0610180A2 (pt) | métodos para prevenir, para tratar, e para tratar ou controlar uma condição associada à inflamação | |
TW200815045A (en) | Pharmaceutical compositions of ropinirole and methods of use thereof | |
IL215897A (en) | Pharmacological preparation in equilibrium containing 4-hydroxy tamoxifen and a method for its preparation | |
TW201247613A (en) | Ester derivatives of bimatoprost compositions and methods | |
Lather et al. | Proniosomal gel-mediated transdermal delivery of bromocriptine: in vitro and ex vivo evaluation | |
JP2019526631A5 (ja) | ||
Täuber et al. | Comparison of the antifungal efficacy of terbinafine hydrochloride and ciclopirox olamine containing formulations against the dermatophyte Trichophyton rubrum in an infected nail plate model | |
JP2010519288A5 (ja) | ||
BRPI0618273A2 (pt) | formulações de dosagem oral de ibuprofeno organolepticamente aceitáveis, métodos de produção e uso das mesmas | |
US20110229535A1 (en) | Composition having a sirtuin activator | |
BR112015018798B1 (pt) | Composição antifúngica tópica para tratar onocomicose | |
CN106470677A (zh) | 用于治疗皮肤学疾病及病症的组成物 | |
JP2009535366A5 (ja) | ||
US20220226310A1 (en) | Bio-Based Medicines and Methods of Increasing Patient Compliance | |
JP5608331B2 (ja) | 熱産生タンパク質発現促進剤 | |
Hascicek et al. | Preparation and evaluation of different gel formulations for transdermal delivery of meloxicam | |
JP2007535505A5 (ja) | ||
JP2003206239A (ja) | 温感組成物及び外用剤組成物 | |
JP5457005B2 (ja) | 外用鎮痛組成物 | |
KR20180098104A (ko) | 에틸 페룰레이트를 유효성분으로 포함하는 알러지 완화용 조성물 |